TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03920579
Drug: CKD-386 formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study: NCT03920579
Drug: D326, D337 and D013
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
Study: NCT03566316
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00645853
Drug: AZD0837
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
Study: NCT03896594
Drug: HL237
Normalized name: Hydrocodone/Levorphanol 237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT03896594
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with same properties except for active ingredient
Study: NCT00408356
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06098313
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 (for 2 days)
Study: NCT01161147
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam Tablets 15 mg
Study: NCT01691001
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00679302
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
Study: NCT03440021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical in appearance to experimental drug, not psycho-active
Study: NCT01566435
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01942135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
Study: NCT00600483
Drug: gentamicin-collagen sponge dipped in saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-cm2 sponge
Study: NCT01360086
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
Study: NCT01360086
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02772822
Drug: SCT400 plus CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03956420
Drug: Preoperative period
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre
Study: NCT03956420
Drug: Intraoperative period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.
Study: NCT03956420
Drug: Intraoperative period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 30 mg i.v. after induction of anaesthesia
Study: NCT03956420
Drug: Intraoperative period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 1.5 MAC higher in patients \< 60 years old
Study: NCT03956420
Drug: Intraoperative period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field
Study: NCT03956420
Drug: Intraoperative period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
Study: NCT00005850
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
Study: NCT00396162
Drug: probiotic containing L.rhamnosus R0011 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
Study: NCT00059332
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
Study: NCT01481025
Drug: Cimicifuga + Hiperico
Normalized name: Actaea cimicifuga root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months
Study: NCT01481025
Drug: Aplause®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
Study: NCT01162421
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
Study: NCT04147208
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered RTV 100 mg orally three times daily in fed state
Study: NCT00766480
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00147199
Drug: Placebo inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses are titrated to 9 breaths four times daily.
Study: NCT00653822
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and SC
Study: NCT04162899
Drug: Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
Study: NCT02333123
Drug: Placebo (for Aspirin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
Study: NCT04621617
Drug: Standard medical therapy (SMT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
Study: NCT03002935
Drug: BPM31510 Oral Nanosuspension 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
Study: NCT01850524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IXAZOMIB matching-placebo capsules.
Study: NCT00595140
Drug: combination with dopamine agonist cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, 0.5mg, one time
Study: NCT04327388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Study: NCT01816581
Drug: Oxynorm
Normalized name: Oxynorm
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03310970
Drug: Lidoderm 5% patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will wear three Lidoderm® topical patches for 12 hours.
Study: NCT04352062
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01110200
Drug: ADVAIR DISKUS 250/50 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
Study: NCT01110200
Drug: SEREVENT 50 mcg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
Study: NCT02163174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
Study: NCT01964235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally and continuously on a twice a day dosing schedule.
Study: NCT00751751
Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
Study: NCT00751751
Drug: losartan + hydrochlorothiazide, if necessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
Study: NCT00170729
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02754089
Drug: Rhus Coriaria L.(Rhus)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg twice daily after meals for 6 weeks
Study: NCT02754089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg twice daily after meals for 6 weeks
Study: NCT00488176
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03291145
Drug: Beta Blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: With and without Beta Blockers
Study: NCT03291145
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brisk Standing before and after seven days treatment with Spironolactone
Study: NCT02586350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo p.o. qd
Study: NCT01997463
Drug: Supervised asthma therapy in schools
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy observed daily in school. Asthma education by American Lung Association
Study: NCT01753856
Drug: Demeclocycline
Normalized name: Demeclocycline
DrugBank: Demeclocycline (DB00618)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01753856
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01753856
Drug: Calcium Supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03694821
Drug: Hylan G-F 20
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: One knee injection of Hylan G-F 20 (Synvisc-One)
Study: NCT01716572
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
Study: NCT00609596
Drug: GI198745
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01507376
Drug: recombinant hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant hCG(250 µg Ovitrell)
Study: NCT01507376
Drug: recombinant hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant hCG(500 µg Ovitrell)
Study: NCT02551276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06350825
Drug: ADT+second-generation antiandrogens ± chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC(Triplet or doublet therapy) for mHSPC
Study: NCT01557166
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
Study: NCT05223361
Drug: Six percent hydroxy ethyl starch 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% HES 130/0.4 additive to ringer lactate as prime solution
Study: NCT05223361
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate as prime solution
Study: NCT00006465
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
Study: NCT02180321
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
Study: NCT02704091
Drug: Smecta
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02704091
Drug: Smecta placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02751905
Drug: BIIB074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as specified in treatment arm
Study: NCT00563342
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
Study: NCT03742037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
Study: NCT03724955
Drug: Estradiol 2 mg
Normalized name: estradiol 2 MG
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
Study: NCT02679729
Drug: AZD5634 for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
Study: NCT02679729
Drug: AZD5634 for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
Study: NCT00114504
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 5-10 mg/day
Study: NCT01576458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02993562
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Normal treatment with levothyroxine.
Study: NCT00003953
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
Study: NCT00002581
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002581
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003953
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV on days 1, 15, and 29.
Study: NCT00002581
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01658657
Drug: lisinopril/hydrochlorothiazide
Normalized name: lisinopril/hydrochlorothiazide 20 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a combination pill
Study: NCT01044186
Drug: ICL670
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04411680
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for COVID-19
Study: NCT01535053
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01535053
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV and IM
Study: NCT04381598
Drug: stevia rebaudiana bertoni
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
Study: NCT02373462
Drug: other anti-hypertensive drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
Study: NCT02664753
Drug: 56 days of weight-adjusted L-Carnitine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.~Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes~For the next 46 days, patients will take oral doses of L-Carnitine as follows:~\< à 60kg : 2g/day \> 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization
Study: NCT04535544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to JNJ-73763989 will be administered as a SC injection.
Study: NCT02664753
Drug: 10 days of intravenous placebo (isotonic saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening.
Study: NCT06241222
Drug: Probiotic Blend Oral Tablet
Normalized name: Probiotic Blend Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
Study: NCT01124786
Drug: CO-1.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
Study: NCT03245658
Drug: THC and CBD Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually titrated doses on daily basis
Study: NCT00354419
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00284518
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
Study: NCT04883996
Drug: 1% EXP039
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),
Study: NCT03777878
Drug: placebo to TA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo ampoules to TA in 100 ml saline by slow infusion
Study: NCT03046550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00111345
Drug: Anthracyclines
Normalized name: Anthracyclines and related substances
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x12 mg/qm
Study: NCT02386358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at a dose 5 m/Kg/day until 60 days
Study: NCT00694408
Drug: methyl prednisolone, hydrocortisone, prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be specific dependant on weight of patients
Study: NCT00750243
Drug: LT-NS001
Normalized name: LT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg b.i.d. p.o. for 7.5 days
Study: NCT00750243
Drug: Naprosyn®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg b.i.d. p.o. for 7.5 days
Study: NCT00872534
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325mg once a day for 7 days
Study: NCT02734940
Drug: Unrestricted Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No changes to current practices, using unlimited narcotic medications intraoperatively.
Study: NCT00987220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03188445
Drug: ferrous fumarate with ascorbic acid
Normalized name: ascorbic acid / ferrous fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06040372
Drug: LB64640
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.
Study: NCT06040372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is provided as a matching placebo
Study: NCT00931489
Drug: ranibizumab (Lucentis(R))
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months